AgomAb Therapeutics (NASDAQ:AGMB) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen downgraded shares of AgomAb Therapeutics (NASDAQ:AGMB) from a hold rating to a sell rating in a report published on Saturday morning.

AGMB has been the subject of a number of other reports. B. Riley Financial started coverage on AgomAb Therapeutics in a research note on Thursday, July 23rd. They issued a “buy” rating and a $34.00 price objective for the company. HC Wainwright began coverage on AgomAb Therapeutics in a report on Monday, June 22nd. They set a “buy” rating and a $35.00 target price for the company. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.00.

AgomAb Therapeutics Trading Down 5.2%

Shares of AGMB stock opened at $13.22 on Friday. The business has a 50 day moving average of $12.52. AgomAb Therapeutics has a one year low of $8.75 and a one year high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last posted its earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter. Equities analysts expect that AgomAb Therapeutics will post -1.77 earnings per share for the current year.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.